Soligenix to Present at the 2021 BIO CEO & Investor Digital Conference
News provided by
Share this article
Share this article
PRINCETON, N.J., Feb. 11, 2021 /PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the BIO CEO & Investor Digital Conference taking place February 16-18, 2021. The presentation will be available to registered conference attendees for on-demand viewing beginning February 15, 2021 at 9:00 AM EST via the virtual conference link. Alternatively, an audio webcast of the Soligenix corporate presentation is available on the Company s website via this link.
(0)
First Patient to Receive ORL-101 in Israel This Week
BAAR, Switzerland, Feb. 8, 2021 /PRNewswire/ Orpha Labs AG today announced its compassionate use program to make ORL
-101 available to physicians providing care for Leukocyte Adhesion Deficiency Type II (LAD-II) patients. ORL-101 is a novel formulation of an ultra-pure L-fucose currently in development for the treatment of LAD II patients.
The Israeli Ministry of Health (MOH) approved the use of ORL-101 for LAD-II patients under Orpha Labs compassionate use program. Orpha Labs expects to enroll LAD-II patients in a Phase III trial soon.
Orpha Labs Founder and Chief Executive Officer Alp Bugra Basat, MD, said,
PRINCETON, N.J., Feb. 1, 2021 /PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Hong Kong Registrar of Patents has granted a patent for the application titled Formulations and Methods of Treatment of Skin Conditions (No. 16102842.8), published on January 29, 2021 under Publication No. 1214771 B. The granted claims are directed to the therapeutic use of synthetic hypericin in the treatment of cutaneous T-cell lymphoma (CTCL), similar to those granted in Europe in 2020. Synthetic hypericin is the active pharmaceutical ingredient in SGX301, the Company s photodynamic therapy, for which positive primary endpoint results in a pivotal Phase 3 study for the treatment of CTCL were recently announced (available here). This new patent is the first granted in Hong Kong and expands on So
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low .
VALNEVAJanuary 25, 2021 GMT
Saint-Herblain (France), Sao Paulo, (Brazil), January 25, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, and Instituto Butantan, producer of immunobiologic products, today announced the signing of definitive agreements for the development, manufacturing and marketing of Valneva’s single-shot chikungunya vaccine, VLA1553, in Low and Middle Income Countries (LMICs). This finalization follows the signing of a binding term sheet in May 20201. The collaboration falls within the framework of the $23.4 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 20192.
SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, and Instituto Butantan, producer of immunobiologic products, today announced the signing of definitive agreements for the development, manufacturing and marketing of Valneva’s single-shot chikungunya vaccine, VLA1553, in Low and Middle Income Countries (LMICs). This finalization follows the signing of a binding term sheet in May 2020
1. The collaboration falls within the framework of the $23.4 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2019
2.
Under the collaboration, Valneva will transfer its chikungunya vaccine technology to Instituto Butantan, who will develop, manufacture and commercialize the vaccine in LMICs. In addition, Instituto Butantan will provide certain clinical and Phase 4 observational studies that Valneva will use to meet regulatory requireme